<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Earnings Report on FinanClub</title>
    <link>https://finan.club/tags/earnings-report/</link>
    <description>Recent content in Earnings Report on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Wed, 21 Feb 2024 09:03:38 +0000</lastBuildDate><atom:link href="https://finan.club/tags/earnings-report/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>MPW</title>
      <link>https://finan.club/us/mpw/</link>
      <pubDate>Wed, 21 Feb 2024 09:03:38 +0000</pubDate>
      
      <guid>https://finan.club/us/mpw/</guid>
      <description>score:112
Chances: Investors looking to own winning stocks need to know which sectors are outperforming other sectors when making purchase decisions. The upheavals of 2023 rattled the housing market, witnessing soaring mortgage rates and stalled sales. A silver lining emerges with mortgage rates finally relenting and a subtle yet promising upswing in home sales.</description>
    </item>
    
    <item>
      <title>CRSP</title>
      <link>https://finan.club/us/crsp/</link>
      <pubDate>Fri, 16 Feb 2024 09:03:20 +0000</pubDate>
      
      <guid>https://finan.club/us/crsp/</guid>
      <description>score:31
Chances: CRISPR Therapeutics has shown improving price performance, earning an upgrade to its IBD Relative Strength Rating. The company is focused on creating transformative gene-based medicines for serious diseases, and has announced conditional marketing authorization for its gene edited therapy, CASGEVY. Risks: The company doesn&amp;rsquo;t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.</description>
    </item>
    
    <item>
      <title>MRK</title>
      <link>https://finan.club/us/mrk/</link>
      <pubDate>Tue, 06 Feb 2024 09:06:04 +0000</pubDate>
      
      <guid>https://finan.club/us/mrk/</guid>
      <description>score:126
Chances: Merck &amp;amp; Co. has demonstrated its commitment to expanding its animal health business through the recent acquisition of Elanco&amp;rsquo;s aqua business. The company&amp;rsquo;s strong earnings report and solid guidance indicate that it is well-positioned to thrive despite potential challenges such as the expiration of its patent on Keytruda.</description>
    </item>
    
  </channel>
</rss>
